PD-L1 Expression As a Predictor of Response to Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer. J Evid Based Med Res 2026, 2 (03), 58-69. https://doi.org/10.66687/jebmr.2.03.2026.43.